Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial
Introduction Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease (ESRD) in the USA and worldwide. Recent experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) may decrease progression of chronic kidney disease. H...
Saved in:
| Main Authors: | Rajiv Agarwal, Ian Craig, Domenic J Reda, Grant D Huang, Kimberly Carlson, David J Leehey, Christina Clise, Todd A Conner, James S Kaufman, Robert J Anderson, Douglas Lammie, Jeffrey Huminik, Linda Polzin, Conor McBurney, Nicholas V Emanuele |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/8/e053019.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Walking or Walking-with-Poles Training on Tissue Oxygenation in Patients with Peripheral Arterial Disease
by: Eileen G. Collins, et al.
Published: (2012-01-01) -
Effects of pentoxifylline on mouse oocytes maturation and qualityin vitro
by: Wu Junjiao, et al.
Published: (2025-03-01) -
Efficacy of using pentoxifylline in patients undergoing breast cancer surgery
by: Samar A. Dewidar, et al.
Published: (2025-07-01) -
Pentoxifylline in Dogs With Osteoarthritis: Comparative Treatment and Efficacy Analysis With Meloxicam
by: Kurtuluş Parlak, et al.
Published: (2025-07-01) -
Mechanism of pentoxifylline mediated down-regulation of killer lineage cell functions
by: R. S. Parhar, et al.
Published: (1993-01-01)